Therefore, we asked whether low Mcl-1 expression levels in AML cells make these cells a priori more vulnerable to antimitotic treatment when the application of an antimitotic agent and a proteasome inhibitor are combined. This evidence concerns the gene MCL1 and acute myeloid leukemia.